Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Laryngoscope. 2015 Sep 15;126(4):786–790. doi: 10.1002/lary.25604

Table II.

Profile of HHT patients by gene status.

HHT2 HHT1 p
Number of telangiectases avg (range) avg (range)
    Face 2.7 (0-24) 2.8 (0-56) 0.9618
    Lips 4.2 (0-36) 5.7 (0-36) 0.1561
    Mouth 4.5 (0-30) 4.9 (0-50) 0.7459
    Hands 18.8 (0-165) 13.6 (0-129) 0.2306
Age of onset for epistaxis 12.2 (1-48) 9.4 (1-47) 0.0047
Age at first intervention 43.8 41.5 0.5845
Treatments/Interventions
    Oral iron 39.0% 23.9% 0.0321
    Iron infusion 19.5% 12.7% 0.2222
    RBC transfusion 22.8% 12.7% 0.0849
    Laser or cautery (electric or chemical) 52.8 36.6 0.0291
    Young's procedure or septal dermoplasty 10.6 7 0.4147
ESS range 3.94 (0-10) 3.18 (0-9.1) 0.0434
    Mild (1-3) 50.8% 52.6% 0.8162
    Moderate (3-7) 38.3% 40.4% 0.7898
    Severe (7-10) 10.9% 7.0% 0.4062

Abbreviations:

• ESS- epistaxis severity score

• HHT- hereditary hemorrhagic telangiectasia